• 1. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 2. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 3. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Thiophenes 2,5-disubstituted thiophenes

Recent Advances in the Study of 2-(5-ethylthiophen-2-yl)ethan-1-ol (CAS: 857362-67-5) in Chemical Biology and Pharmaceutical Research

The compound 2-(5-ethylthiophen-2-yl)ethan-1-ol (CAS: 857362-67-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and potential applications in drug development. The compound's thiophene-based structure, coupled with the ethyl and hydroxyl functional groups, makes it a promising candidate for further investigation in medicinal chemistry.

Recent studies have explored the synthetic pathways for 2-(5-ethylthiophen-2-yl)ethan-1-ol, with a focus on optimizing yield and purity. A 2023 publication in the Journal of Medicinal Chemistry detailed a novel catalytic method that significantly improves the efficiency of its synthesis, reducing byproduct formation and enhancing scalability. This advancement is particularly relevant for industrial applications, where large-scale production of high-purity compounds is essential. The study also highlighted the compound's stability under various conditions, which is a critical factor for its potential use in pharmaceutical formulations.

In terms of biological activity, preliminary in vitro studies have demonstrated that 2-(5-ethylthiophen-2-yl)ethan-1-ol exhibits moderate inhibitory effects on certain inflammatory pathways. A 2022 study published in Bioorganic & Medicinal Chemistry Letters reported that the compound interacts with key proteins involved in the NF-κB signaling pathway, suggesting its potential as an anti-inflammatory agent. However, further in vivo studies are required to validate these findings and assess the compound's pharmacokinetic properties, including absorption, distribution, metabolism, and excretion (ADME).

Another area of interest is the compound's potential role in central nervous system (CNS) disorders. A 2023 research paper in ACS Chemical Neuroscience explored its interaction with GABA receptors, indicating possible anxiolytic or sedative effects. While the results are preliminary, they open new avenues for investigating 2-(5-ethylthiophen-2-yl)ethan-1-ol as a scaffold for developing novel CNS-targeting therapeutics. The study also noted the compound's ability to cross the blood-brain barrier, a crucial property for CNS drug candidates.

Despite these promising findings, challenges remain in the development of 2-(5-ethylthiophen-2-yl)ethan-1-ol as a therapeutic agent. Current research gaps include a lack of comprehensive toxicity studies and limited data on its long-term effects. Future studies should focus on addressing these gaps, as well as exploring structure-activity relationships (SAR) to optimize its biological activity. Collaborative efforts between academic and industrial researchers will be essential to advance the compound's development and translate laboratory findings into clinical applications.

In conclusion, 2-(5-ethylthiophen-2-yl)ethan-1-ol (CAS: 857362-67-5) represents a promising compound in chemical biology and pharmaceutical research, with potential applications in inflammation and CNS disorders. Continued research efforts are needed to fully elucidate its mechanisms of action, optimize its therapeutic potential, and overcome existing challenges in its development. This brief underscores the importance of interdisciplinary collaboration and innovative approaches in advancing the field of medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)